New Delhi based Super Religare Laboratories Limited (SRL) has informed the share market (BSE/NSE) that they have planning to enter the capital market with its maiden public issue of 28,000,000 equity shares of Rs 10 each. The issue constitutes 35% post issue paid up capital of the company. The company has filed a Draft Red Herring Prospectus (DRHP) on 15th February 2011 with market regulator Securities and Exchange Board of India (SEBI). The premium to be decided via 100% book building process. The IPO launching date is depend on the market conditions as per company sources. Super Religare Laboratories Limited (Formerly SRL Ranbaxy Ltd.) is the largest and most trusted pathology laboratory network in India, servicing nearly 1550 hospitals/path labs and over 50,000 doctors.
The proceeds of the IPO amount would be used by the company to provide Rs.150 Cr loan to its subsidiary Piramal Diagonostic Services Private Limited (PDPSL) for repayment of its existing debt to Kotak Mahindra Bank, Rs.165 Cr for redemption of NCDs allotted to Piramal Healthcare Limited (former parent company of PDPSL), Rs.110 Cr for redemption of non-cumulative redeemable preference shares allotted to one of its promoters – Oscar Investments Limited (OIL), Rs.69 Cr for repayment of outstanding debt to Religare Finvest Ltd and for other general corporate purposes.
The Equity Shares are proposed to be listed on the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE).
The Book running lead managers to the issue are Nomura Financial Advisory, Kotak Mahindra Capital and Religare Capital Markets.
Registrar of the Issue : Link Intime India Private Limited.
Stay tuned to BelltheBull Blog for more news on Super Religare Laboratories IPO !Google+